Clinical Indications of Use
The suite of ReelECG monitoring solutions such as the ReelWearable+ Plus is now being adopted to replace many of the common indications of use that have been used for traditional 24 hour Holter monitoring. With virtually all of the recent clinical data suggesting improved diagnostic yield with longer duration AECG studies, most clinicians are choosing a wearable ECG patch as a primary method of monitoring their patients compared to just a 24 hour study. With the ReelCardio ReelWearable+ Plus, clinicians will have 3 – 30 times more ECG information to obtain a greater picture of the patients ECG activity.
The ReelWearable+ Plus provides clinical evaluation for patients suspected of experiencing a variety of transient cardiac arrhythmias. Patient’s monitored with the ReelWearable+ Plus should not be those with life threatening arrhythmias such as sustained supraventricular / ventricular tachycardia and other known complicated rhythms.
Patients that qualify for the ReelECG ReelWearable+ Plus include:
- Palpitations
- Dizziness
- Syncope
- Pre-Syncope
- Chest Pain
- Shortness of Breath
- Patients with suspected non-sustained arrhythmias
- Patients whom may develop atrial fibrillation (A Fib)
- Chronic Fatigue (common in women’s heart disease)
- Patients Post-Surgery
- Post Myocardial Infarction
In contrast to a fixed picture of cardiac electrical activity from a standard resting 12-Lead Electrocardiogram & the standard 24 hour Holter monitor, the extended continuous ambulatory ECG monitoring (such as LTH or MCT) with the ReelCardio V-Patch (3 – 30 days).
More information: